IL1B and COVID-19: Therefore, it was recommended to restrict the tocilizumab treatment to patients with high IL-6 levels (“WHO R&D Blueprint COVID-19 Informal Consultation on the Potential Role of IL-6/IL-1 Antagonists in the Clinical Management of COVID 19 Infection” 2020) (Michot et al., 2020).